Tumor endothelial cell abnormalities
肿瘤内皮细胞异常
基本信息
- 批准号:8325609
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAdultAngiogenesis InhibitorsBloodBlood CirculationBlood VesselsBone MarrowBone Marrow AblationBreast CarcinomaCell LineCellsClinicClinical ResearchClinical TrialsClone CellsDissectionDrug resistanceDrug usageEmployee StrikesEndothelial CellsEndotheliumEngraftmentGenesGoalsHeterogeneityHomingHumanKnowledgeLaboratoriesLasersMammary NeoplasmsMesenchymal Stem CellsMolecularMolecular ProfilingMouse Mammary Tumor VirusMusMyeloid CellsNeoplasm MetastasisNeoplasmsNeoplasms in Vascular TissueNutrientOxygenPECAM1 geneProstate carcinomaProstatic NeoplasmsStem cellsTestingTransgenic MiceTumor Biologyantiangiogenesis therapybasebonecalcificationcancer therapycell typedesignfeedingmineralizationmouse modelneoplastic cellnovelprogenitorprogramstumortumor progression
项目摘要
The idea that tumors could be eradicated by destroying tumor-associated blood vessels was first proposed
over 30 years ago. Today there are about 11 anti-angiogenic drugs in clinical trials. But the results of most
clinical studies to date have so far been disappointing. The idea behind anti-angiogenesis (anti-endothelial)
therapy is that the endothelial cells lining tumor blood vessels are homogeneous, normal, are not mutable,
and wlll not develop drug resistance in contrast to tumor cells. However, that basic assumption has been
challenged by recent studies showing morphological and molecular changes (e.g. ectopic calcification) and
striking heterogeneity in tumor-specific endothelial cells. Endothelial cells conscripted by a growing tumor
may evade anti-angiogenic strategies through diverse, acquired mechanisms. For example, tumor-specific
endothelial cells may be derived from multiple cell types. Including sprouting endothelium, bone marrowderived
vascular progenitors, trans-differentiated myeloid cells, and multi-potent mesodermal stem cells. It is
surprising, then, that most anti-angiogenic therapies today are routinely tested on normal endothelial cell
lines in the laboratory. To address this problem, our goals are: 1) To use transgenic mouse models of breast
and prostate carcinoma to isolate and characterize tumor-specific endothelial cells from breast and prostate
tumors. 2) To determine the relationship between tumor blood vessel calcification and tumor progression
and metastasis. 3) To determine the tumor-specific "homing" and vascular differentiation potential of adult
mesenchymal stem cells in tumor-bearing mice. 4) And to use laser capture micro-dissection and microarrays
to identify a molecular signature in tumor-specific endothelial cells as tumors progress from the
earliest neoplasia to adenocarcinoma. It Is not known why anti-angiogenic therapies, which hold great
promise in the treatment of cancer, have not succeeded in the clinic. Our study seeks to better understand
the biology of tumor-specific endothelial cells through rigorous characterization of freshly Isolated cells and
high-throughput gene analysis to identify novel genes and gene networks. The long-term goal Is to use this
new knowledge for the rational design of more effective anti-angiogenic strategies.
肿瘤可以通过破坏肿瘤相关血管来根除的想法首次被提出。
30多年前。今天,大约有11种抗血管生成药物正在进行临床试验。但大多数人的结果
到目前为止,临床研究一直令人失望。抗血管生成(抗内皮细胞)背后的理念
治疗方法是使肿瘤血管内皮细胞均匀、正常、不变,
与肿瘤细胞相比,不会产生抗药性。然而,这一基本假设是
最近的研究显示形态和分子变化(例如异位钙化)和
肿瘤特异性内皮细胞的显著异质性。生长中的肿瘤征募内皮细胞
可能通过不同的获得性机制逃避抗血管生成策略。例如,肿瘤特异性
内皮细胞可能来源于多种细胞类型。包括发芽内皮、骨髓源性
血管祖细胞、跨分化髓系细胞和多潜能中胚层干细胞。它是
令人惊讶的是,如今大多数抗血管生成疗法都是在正常内皮细胞上进行常规测试
在实验室里排好队。为了解决这个问题,我们的目标是:1)使用转基因小鼠的乳房模型
和前列腺癌从乳腺和前列腺癌中分离和鉴定肿瘤特异性内皮细胞
肿瘤。2)确定肿瘤血管钙化与肿瘤进展的关系
和转移。3)确定成人肿瘤特异性“归巢”和血管分化潜能
荷瘤小鼠体内的间充质干细胞。4)使用激光捕获显微解剖和微阵列
为了确定肿瘤特异性内皮细胞在肿瘤从
最早的肿瘤转变为腺癌。目前尚不清楚为什么有效的抗血管生成疗法
在治疗癌症方面有希望,但在临床上都没有成功。我们的研究试图更好地理解
肿瘤特异性内皮细胞的生物学通过对新鲜分离的细胞和
高通量基因分析,以确定新的基因和基因网络。长期目标是利用这一点
为合理设计更有效的抗血管生成策略提供新的知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Carl Dudley其他文献
Andrew Carl Dudley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Carl Dudley', 18)}}的其他基金
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10356164 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10179715 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10573196 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8693221 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8887312 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10399410 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10092966 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10621205 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
7708266 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
8231654 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别: